Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135874

Published: 2020

Journal Articles

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

Maria Gavriatopoulou, Andriani Boultadaki, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Charis Bourgioti, Panagiotis Malandrakis, MD, Despina Fotiou, BMBS, MA, Magdalini Migkou, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Efstathios Kastritis, MD, Evangelos Terpos, MDPhD, Meletios A. Dimopoulos, MD, Lia A. Moulopoulos, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136256

Published: 2020

Journal Articles

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Despina Fotiou, BMBS, MA, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Panagiotis Malandrakis, MD, Foteini Theodorakakou, MD, Ioanna Dialoupi, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Roussou, MD, Evangelos Terpos, MDPhD, Meletios A. Dimopoulos, MD, Efstathios Kastritis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136323

Published: 2020

Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-134928

Published: 2020

Journal Articles

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Judith Trotman, FRACP, Christian Buske, MD, Alessandra Tedeschi, MD, Jeffrey V. Matous, MD, David MacDonald, MD, Constantine Tam, MBBS, Olivier Tournilhac, MD PhD, Shuo Ma, MD PhD, Steven P. Treon, MD PhD, Albert Oriol, Jerry Ping, PhD, Eva M. Briso, PhD, Israel Arango-Hisijara, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-133916

Published: 2020

Journal Articles

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Despina Fotiou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Foteini Theodorakakou, MD, Maria Roussou, MD, Evangelos Terpos, MD PhD, Efstathios Kastritis, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-136248

Published: 2020

Journal Articles

Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Sara Bringhen, MD, Luděk Pour, MD, Reuben Benjamin, MBBS, FRCPath, PhD, Sebastian Grosicki, MD PhD, Chang-Ki Min, MD PhD, Danielle Leao Cordeiro De Farias, MDMSc,MBA, Alexander Vorog, MD, Richard J Labotka, MD, Bingxia Wang, PhD, Dasha Cherepanov, Lauren E. Cain, MHS, ScM, PhD, Sudhakar Manne, S. Vincent Rajkumar, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136293

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Marie José Kersten, MD PhD, Monique C. Minnema, Josephine M. Vos, MD PhD, Kazem Nasserinejad, Marcel Kap, BSc, Eftathios Kastritis, Maria Gavriatopoulou, MD, Martine E.D. Chamuleau, Dries Deeren, MD PhD, Lidwine Winnifred Tick, MD PhD, Jeanette K. Doorduijn, MD PhD, Fritz Offner, MD, Lara H Bohmer, MD, Karima Amaador, MD, Roberto D Liu, BSc, Steven T Pals, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 344.

https://doi.org/10.1182/blood-2019-122365

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

Eftathios Kastritis, Ioannis Papassotiriou, PhD, Maria Roussou, MD, Maria Gavriatopoulou, MD, Mantzou Aimilia, PhD, Erasmia Psimenou, MD, Smaragdi Marinaki, Charikleia Gakiopoulou, MD, Alexandra Margeli, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Gerasimos-Petros Papassotiriou, PhD, Aristea-Maria Papanota, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3126.

https://doi.org/10.1182/blood-2019-125305

Published: 2019

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 3120.

https://doi.org/10.1182/blood-2019-124349

Published: 2019

Journal Articles

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Salmon Manier, Meletios A. Dimopoulos, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Michel Delforge, Katja C. Weisel, MD, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Bruno Costa, Suzanne Robinson, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 3122.

https://doi.org/10.1182/blood-2019-124557

Published: 2019

Journal Articles

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Evangelos Terpos, MD PhD, Ioannis V. Kostopoulos, Aristea-Maria Papanota, MD, Konstantinos Papadimitriou, BSc, Panagiotis Malandrakis, MD, Paraskevi Micheli, BSc, Ioannis Ntanasis-Stathopoulos, MD, Despina Fotiou, MD, Andreas Metousis, BSc, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Eftathios Kastritis, Ourania E. Tsitsilonis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4338.

https://doi.org/10.1182/blood-2019-127989

Published: 2019

Journal Articles

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Bachisio Ziccheddu, PhD, Giulia Biancon, Chiara De Philippis, MD, Filippo Bagnoli, MD, Francesco Maura, MD, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi, Carolina Terragna, Marina Martello, Tina Bagratuni, PhD, Eftathios Kastritis, Meletios A. Dimopoulos, MD, Michele Cavo, Cristiana Carniti, PhD, Vittorio Montefusco, Paolo Corradini, Niccolo Bolli, MD PhD

Blood (2019) 134 (Supplement_1): 3056.

https://doi.org/10.1182/blood-2019-122197

Published: 2019

Journal Articles

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Blood (2019) 134 (Supplement_1): 3066.

https://doi.org/10.1182/blood-2019-126867

Published: 2019

Journal Articles

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Panagiotis Efentakis, PhD, Ioanna Andreadou, PhD, Panagiota-Efstathia Nikolaou, PhD, Claudius Witzler, Svenja Siemer, Eftathios Kastritis, Philip Wenzel, MD PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 3797.

https://doi.org/10.1182/blood-2019-123522

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 2528.

https://doi.org/10.1182/blood-2019-123338

Published: 2019

Journal Articles

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Loula Papageorgiou, Patrick Van Dreden, PhD, Meletios A. Dimopoulos, MD, Annette Larsen, Mohamad Mohty, MD PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas

Blood (2019) 134 (Supplement_1): 2425.

https://doi.org/10.1182/blood-2019-124650

Published: 2019

NARROW

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only